Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly plans new 2 billion euro German plant -source
06:26am, Thursday, 16'th Nov 2023
U.S. pharmaceuticals company Eli Lilly plans to build a new plant in western Germany, sources close to the matter told Reuters, with one putting the investment at 2 bln euros
Eli Lilly: Perfectly Priced Healthcare Giant
06:19am, Thursday, 16'th Nov 2023
Eli Lily has the highest market capitalization of any Healthcare company, but its low revenue does not justify its lofty valuation at first glance. However, the company's average 5-year forward growth
Eli Lilly plans to invest 2 bln euros in new German plant -source
05:17am, Thursday, 16'th Nov 2023
U.S. pharma company Eli Lilly plans to invest 2 billion euros ($2.17 billion) in a new plant in Alzey, western Germany, a source close to the negotiations told Reuters on Thursday.
Why Eli Lilly Stock Flopped While the Market Popped Today
06:00pm, Wednesday, 15'th Nov 2023
A media report stated that the pharmaceutical giant intends to build a new factory in Germany. It will apparently fund the project entirely on its own.
Lilly plans single-digit billion dollar new German plant - sources
02:04pm, Wednesday, 15'th Nov 2023
U.S. pharma giant Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a pres
Investors increase holdings of weight-loss drug makers' shares in Q3 -filings
06:46pm, Tuesday, 14'th Nov 2023
Some big investors showed increased appetite for weight-loss drug makers in the third quarter, piling in to shares of Eli Lilly and Novo Nordisk amid growing demand for their product, securities filin
Why It's Time to Sell These 3 Hot Stocks
04:06pm, Tuesday, 14'th Nov 2023
Stock gains are great, but they don't necessarily continue forever. Today's fast rising investment can be tomorrow's disappointment.
Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds
03:34pm, Tuesday, 14'th Nov 2023
For workers in employer-sponsored health plans, coverage of Wegovy and other GLP-1 medications for weight loss is lagging far behind coverage of that class of drugs for diabetes, a new survey shows.
Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning
07:45am, Tuesday, 14'th Nov 2023
Eli Lilly's weight-loss medicine Zepbound was just approved for sale by regulators. It's buying businesses and making investments to drive further growth.
Jim Cramer explains why he favors Eli Lilly in the weight loss drug space
07:48pm, Monday, 13'th Nov 2023
'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.
Jim Cramer weighs the market impact of Eli Lilly and Novo Nordisk's weight loss drugs
07:47pm, Monday, 13'th Nov 2023
'Mad Money' host Jim Cramer compares the weight loss drug offerings from Novo Nordisk and Eli Lilly and talks what investors need to know about both companies.
Jim Cramer says insurance companies will pay for 'revolutionary' weight-loss drugs for their members
07:04pm, Monday, 13'th Nov 2023
CNBC's Jim Cramer on Monday emphasized his belief that companies making GLP-1 diabetes and obesity drugs will be valuable.
Eli Lilly rides on Novo's coattails as BofA analysts maintain ‘Buy' rating following SELECT trial data
01:42pm, Monday, 13'th Nov 2023
Novo Nordisk (NYSE:NVO) presented the full results from its SELECT cardiovascular trial at an American Heart Association (AHA) meeting on Saturday and analysts at Bank of America (BofA) Securities sai
Eli Lilly's experimental drug lowers risk of heart disease by 94%: study
01:42pm, Monday, 13'th Nov 2023
Pharmaceutical giant Eli Lilly's experimental vaccine-like drug slashed a risk factor for heart disease by a whopping 94% for almost a year, according to a report.
Eli Lilly's experimental heart drug cuts genetic risk factor by 94% for a year
11:42am, Monday, 13'th Nov 2023
Eli Lilly and Co (NYSE:LLY)'s experimental therapy lepodisiran reduced the harmful risk factor for lipoprotein (a) by up to 94% for up to a year with just a single dose, data from a first-in-human tri
